Monday, September 10, 2018 - 07:00
  • Updated long term follow-up data and new data from cohort expansion in the Phase I of IPH4102 in advanced CTCL at the EORTC CLTF 2018 Meeting
  • Updated data from Phase I/II fully-enrolled study of monalizumab in combination with cetuximab in SCCHN at the ESMO 2018 congress

 

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that updated data from ongoing clinical trials evaluating first-in-class antibody, IPH4102, and lead asset, monalizumab, partnered with AstraZeneca/MedImmune, will be presented at the EORTC CLTF* 2018 Meeting in St Gallen, Switzerland, September 27-29, 2018 and at the ESMO** 2018 Congress in Munich, Germany, October 19-23, 2018, respectively. Moreover, Eric Vivier, Chief Scientific Officer, is invited to the ESMO Congress as speaker in the Early detection of cancer using minimally invasive biomarkers Special Symposium.

 

EORTC CLTF 2018 for IPH4102:

  • Title: IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study
  • Date and time: September 29, 2018, 8:30 – 9:45
  • Presentation number: 078
  • Session: Oral presentation, Session 8 / Treatment and clinical cases
  • Presenter: Martine Bagot, Principal Investigator and Head of the Dermatology Department at the Saint-Louis Hospital, Paris, France
  • Location: Olma Messen Hall 9.2, St-Gallen, Switzerland

 

ESMO 2018 Congress for monalizumab:

  • Results of a Phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
  • Date and time: October 20, 2018, 15:00
  • Presentation number: 1049PD
  • Session: Poster Discussion session – Head and neck
  • Presenter: Jérôme Fayette, Medical Oncologist at the Centre Léon Bérard Lyon, France
  • Location: Hall B3 – Room 23, ICM München, Munich, Germany
  • Title: Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with Durvalumab plus Monalizumab (anti-NKG2A)
  • Date & time: October 20, 2018, 12:30
  • Presentation number: 1194P
  • Session: Poster Display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research (ID 259)
  • Presenter: Jennifer R. Diamond, Associate Professor, Division of Medical Oncology at the Colorado University, Denver, US
  • Location: Hall A3, Poster Area Networking Hub, ICM München, Munich, Germany

 

  • Title: Changes in the innate immune system as early events in cancer
  • Date & time: October 22, 2018, 15:05 – 15:25
  • Session: Special Symposium Early detection of cancer using minimally invasive biomarkers
  • Presenter: Eric Vivier, Chief Scientific Officer of Innate Pharma, Marseille, France
  • Location: Hall A1 – Room 17, ICM München, Munich, Germany

The full list of events Innate Pharma is participating in is available and regularly updated on the Company’s website in the “Events” section.

 

*European Organisation for Research and Treatment of Cancer and Cutaneous Lymphoma Task Force

**European Society for Medical Oncology

AttachmentSize
PR in English106.38 KB
CP en français109.56 KB